AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 11 min read$BRO

Goldman Sachs Adjusts Price Target on Brown & Brown to $68 From $73, Maintains Neutral Rating

Goldman Sachs reduced its price target for Brown & Brown from $73 to $68, maintaining a neutral rating. The company's stock closed at $60.90, up 0.50% for the day but down 1.30% for the week and 23.59% year-to-date.

Original reporting
marketscreener.com
Published Oct 1, 2026, 10:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BRO
Bearish
high confidence
Mentioned
$BRO
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$BROBearishMed
01

Why it matters

The downgrade may trigger short-term selling, but longer-term fundamentals could differ.

02

Market read

Analyst target cuts are a common catalyst for price moves; traders may adjust positions accordingly.

03

What to watch

Potential upside from upcoming reinsurance deals not reflected in the target.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Goldman Sachs issued a new price target for Brown & Brown, reflecting its revised valuation outlook.

Company-level read

Ticker impact

$BROBearishHigh confidence
Context

Goldman Sachs lowered its price target on Brown & Brown to $68 from $73.

Expected impact

downward pressure as investors price in the lower target

Evidence & confidence

Analyst target reductions historically lead to short-term price declines.

Market effects

Sector

May weigh on the insurance sector as peers watch the downgrade.

Regional

Limited to U.S. markets where Brown & Brown trades.

Global

Low, confined to a single stock.

Counterpoint

What could challenge this read

Target cut could be premature if recent earnings beat expectations.

Key entities

  • Company
    Brown & Brown

    U.S. insurance provider (ticker BRO).

  • Analyst
    Goldman Sachs

    Investment bank providing the price target revision.

Read at source← All news

Related articles

OCT 7
$BROMed

Brown & Brown gets bullish rating as Oppenheimer starts coverage of P&C brokers (BRO:NYSE)

Oppenheimer initiated coverage of property & casualty insurance brokers, rating Brown & Brown (BRO) Outperform and Arthur J. Gallagher (AJG) Sector Perform. The firm expects BRO's organic growth to improve, driven by the Accession acquisition, while noting durable growth prospects for brokerages. However, AJG's margin improvement is expected to stall due to integration and industry challenges.

seekingalpha.com1 min
SEP 16
$BROMedAI 8/10

Winners And Losers Of Q2: Baldwin Insurance Group (NASDAQ:BWIN) Vs The Rest Of The Insurance Brokers Stocks

Ryan Specialty beat estimates but fell 11.1% to $39.20. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates by 2.5%, and dropped 3.4% to $67.32. Arthur J. Gallagher (AJG) reported $4.00B revenue, up 24.3% YoY, missing estimates by 0.5%, and fell 3.3% to $248.05. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates by 1.8%, and dropped 1.2% to $179.91.

finance.yahoo.com2 min
JUL 28
$BROMed

Why Are Brown & Brown (BRO) Shares Soaring Today

Brown & Brown (NYSE: BRO) shares rose about 5% after the company reported Q2 results. Revenue increased 30.4% year over year to $1.68B, slightly below analysts’ $1.72B estimate. Adjusted EPS was $1.07, in line with expectations, driving investor focus on strong growth despite the revenue miss.

financialcontent.com4 min
JUL 28
$BROMed

Brown & Brown Q2 Earnings Call Highlights

Brown & Brown (NYSE:BRO) discussed Q2 results on its earnings call. CFO Andy Watts said Retail revenue rose 35.9% mainly from acquisitions, while Retail organic growth was pressured by a pharmacy consulting business and a litigation-related organic revenue adjustment. Specialty Distribution total revenue rose 28.1% on Accession, with EBITDAC margin down to 42.7%. BRO expects H2 Retail organic growth excluding contingents of 1.5% to 2.5% and Specialty 2% to 4%, and reaffirmed $30M-$40M integratio

yahoo.com7 min
JUL 27
$BROMedAI 8/10

Brown & Brown, Inc. announces second quarter 2026 results, including total revenues of $1.7 billion, an increase of 30.4%; Organic Revenue decrease of 0.7%; growth of Organic Revenue with Contingents

Brown & Brown, Inc. (NYSE:BRO) reported unaudited Q2 2026 results. Total revenues rose to $1.7 billion, up 30.4% year over year, while organic revenue fell 0.7%. Net income attributable to the company increased to $288 million, and diluted EPS was $0.84. For six months, revenues were $3.6 billion, up 33.0%.

thestarphoenix.com6 min